BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Caetano R, Rodrigues PHA, Corrêa MCV, Villardi P, Osorio-de-Castro CGS. The case of eculizumab: litigation and purchases by the Brazilian Ministry of Health. Rev Saude Publica 2020;54:22. [PMID: 32130309 DOI: 10.11606/s1518-8787.2020054001693] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Ivama-brummell AM, Wagner AK, Pepe VLE, Naci H. Ultraexpensive gene therapies, industry interests and the right to health: the case of onasemnogene abeparvovec in Brazil. BMJ Glob Health 2022;7:e008637. [DOI: 10.1136/bmjgh-2022-008637] [Reference Citation Analysis]
2 Caetano R, Cordeiro Dias Villela Correa M, Villardi P, Almeida Rodrigues PH, Garcia Serpa Osorio-de-Castro C. Dynamics of patents, orphan drug designation, licensing, and revenues from drugs for rare diseases: The market expansion of eculizumab. PLoS One 2021;16:e0247853. [PMID: 33667235 DOI: 10.1371/journal.pone.0247853] [Reference Citation Analysis]
3 Nga HS, Palma LMP, Ernandes Neto M, Fernandes-Charpiot IMM, Garcia VD, Kist R, Miranda SMC, Macedo de Souza PA, Pereira GM Jr, de Andrade LGM. Thrombotic microangiopathy after kidney transplantation: Analysis of the Brazilian Atypical Hemolytic Uremic Syndrome cohort. PLoS One 2021;16:e0258319. [PMID: 34748552 DOI: 10.1371/journal.pone.0258319] [Reference Citation Analysis]